Leveraging Continuous Glucose Monitoring Data as an Additional Source for Glucagon Prescription Behavior.

IF 3.7 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Endocrine Practice Pub Date : 2024-10-25 DOI:10.1016/j.eprac.2024.10.012
Jayachidambaram Ambalavanan, Jill Rusticelli, Diana Isaacs, Huijun Xiao, James Bena, Christopher Babiuch, M Cecilia Lansang
{"title":"Leveraging Continuous Glucose Monitoring Data as an Additional Source for Glucagon Prescription Behavior.","authors":"Jayachidambaram Ambalavanan, Jill Rusticelli, Diana Isaacs, Huijun Xiao, James Bena, Christopher Babiuch, M Cecilia Lansang","doi":"10.1016/j.eprac.2024.10.012","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Hypoglycemia can be life-threatening for patients with diabetes (DM). We aimed to 1) evaluate percentage of glucagon prescription in patients with hypoglycemia on CGM reports, and 2) determine incident glucagon prescription after an educational letter delivered to the providers.</p><p><strong>Research design and methods: </strong>The study had two components - retrospective chart review and a quality improvement (QI) component. Chart review was conducted from March-October 2023 on adult patients in a tertiary care health system with type 1 DM, or type 2 DM on insulin, sulfonylurea, or meglitinide. Percentages of pre-existing and incident glucagon prescription were evaluated. For the QI, we contacted providers whose patients had hypoglycemia defined as time below range (TBR) ≥4% on CGM reports without a glucagon prescription and shared the ADA Standards of Care on hypoglycemia along with information about various forms of glucagon. Data on glucagon prescription was collected 4 weeks later.</p><p><strong>Results: </strong>Of the 1,543 patients included 170 had TBR ≥4%. Among them, 37% had pre-existing prescription and 14% incident glucagon prescription, compared with patients without hypoglycemia (p<0.001). Pre-existing or incident glucagon prescription was seen in 28% without hypoglycemia, 38% with mild , 49% with moderate, and 63% with severe hypoglycemia (p<0.001 mild vs severe; moderate vs no hypoglycemia; severe vs no hypoglycemia). Among 70 patients whose providers received education, 27 (39%) prescribed glucagon. Glucagon emergency kit, glucagon autoinjector, and inhaled glucagon were top choices.</p><p><strong>Conclusion: </strong>Glucagon prescription remains suboptimal among patients with hypoglycemia on CGM reports. Provider engagement via QI can increase glucagon prescription.</p>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.eprac.2024.10.012","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Hypoglycemia can be life-threatening for patients with diabetes (DM). We aimed to 1) evaluate percentage of glucagon prescription in patients with hypoglycemia on CGM reports, and 2) determine incident glucagon prescription after an educational letter delivered to the providers.

Research design and methods: The study had two components - retrospective chart review and a quality improvement (QI) component. Chart review was conducted from March-October 2023 on adult patients in a tertiary care health system with type 1 DM, or type 2 DM on insulin, sulfonylurea, or meglitinide. Percentages of pre-existing and incident glucagon prescription were evaluated. For the QI, we contacted providers whose patients had hypoglycemia defined as time below range (TBR) ≥4% on CGM reports without a glucagon prescription and shared the ADA Standards of Care on hypoglycemia along with information about various forms of glucagon. Data on glucagon prescription was collected 4 weeks later.

Results: Of the 1,543 patients included 170 had TBR ≥4%. Among them, 37% had pre-existing prescription and 14% incident glucagon prescription, compared with patients without hypoglycemia (p<0.001). Pre-existing or incident glucagon prescription was seen in 28% without hypoglycemia, 38% with mild , 49% with moderate, and 63% with severe hypoglycemia (p<0.001 mild vs severe; moderate vs no hypoglycemia; severe vs no hypoglycemia). Among 70 patients whose providers received education, 27 (39%) prescribed glucagon. Glucagon emergency kit, glucagon autoinjector, and inhaled glucagon were top choices.

Conclusion: Glucagon prescription remains suboptimal among patients with hypoglycemia on CGM reports. Provider engagement via QI can increase glucagon prescription.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
利用连续葡萄糖监测数据作为胰高血糖素处方行为的额外来源。
目的:低血糖可危及糖尿病(DM)患者的生命。我们的目的是:1)评估 CGM 报告中低血糖患者使用胰高血糖素处方的比例;2)确定向医疗服务提供者发送教育信后的胰高血糖素处方情况:研究包括两个部分:回顾性病历审查和质量改进(QI)部分。从 2023 年 3 月到 10 月,对一家三级医疗保健系统中患有 1 型糖尿病或 2 型糖尿病、正在使用胰岛素、磺脲类药物或格列汀类药物的成年患者进行了病历审查。我们评估了患者使用胰高血糖素前的处方比例和使用胰高血糖素后的处方比例。为了开展 QI,我们联系了在 CGM 报告中低血糖定义为低于量程时间 (TBR) ≥4% 但未开具胰高血糖素处方的患者的医疗服务提供者,并与他们分享了《美国糖尿病协会低血糖护理标准》以及有关各种形式胰高血糖素的信息。4 周后收集胰高血糖素处方数据:结果:在 1543 名患者中,170 人的 TBR ≥4%。结果:在纳入的 1543 名患者中,170 人的总血糖率≥4%,其中 37% 的患者有糖皮质激素处方,14% 的患者有胰高血糖素处方:在 CGM 报告的低血糖患者中,胰高血糖素处方仍未达到最佳水平。医疗服务提供者通过 QI 参与可增加胰高血糖素处方。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Endocrine Practice
Endocrine Practice ENDOCRINOLOGY & METABOLISM-
CiteScore
7.60
自引率
2.40%
发文量
546
审稿时长
41 days
期刊介绍: Endocrine Practice (ISSN: 1530-891X), a peer-reviewed journal published twelve times a year, is the official journal of the American Association of Clinical Endocrinologists (AACE). The primary mission of Endocrine Practice is to enhance the health care of patients with endocrine diseases through continuing education of practicing endocrinologists.
期刊最新文献
Comprehensive Analysis of Mitotane-Related Adverse Events Using the FDA Adverse Event Reporting System. The role of active brown adipose tissue in patients with pheochromocytoma or paraganglioma (PPGL). Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a Real-world Retrospective Analysis. Glucose Disorders in Patients with Pheochromocytoma/Paraganglioma: Profile and influence effects in a large cohort with 705 patients. Loss of Follow-up for Thyroid Nodules in Patients Living in Poverty.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1